EDN1 and congestive heart failure: Moreover, it can be concluded from qualitative analyses that the Fuzi compatibility can reduce the levels of ET-1 and AngII in plasma more effectively than using Fuzi alone and achieve a regulatory effect on the RAAS (Fu et al., 2018), proving that the synergistic compatibility mechanism of Fuzi is related to the regulation of RAAS and inhibition of the excessive activation of neuroendocrine factors, thereby enhancing the effect of anti-CHF.